Jacobson Pharma Corporation Ltd. and JBM (Healthcare) Limited have jointly announced the signing of the 2025 Europharm License Agreement. The agreement follows the expiration of the previous 2020 License Agreement on 30 November 2025. The new license arrangement is considered by the boards of both companies to be in the ordinary and usual course of business, with terms deemed fair, reasonable, and in the best interests of shareholders. The agreement constitutes a continuing connected transaction under Chapter 14A of the Hong Kong Listing Rules. As the applicable percentage ratios are below 5% but the total considerations exceed HK$3,000,000, the agreements are subject to reporting and announcement requirements but are exempt from circular and independent shareholders' approval requirements. Directors with potential conflicts of interest abstained from voting on the relevant resolutions.